Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy
Bioengineering · 15.05.2025 · 12 (5) · 525
DOI: 10.3390/bioengineering12050525 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 15.05.2025. Verfasst von Philip Drohat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, UHealth Sports Medicine Institute, Miller School of Medicine, University of Miami, Miami, FL 33146, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by low-grade inflammation, cartilage breakdown, and persistent pain. Despite its prevalence, current therapeutic strategies primarily focus on symptom management rather than modifying disease progression. Monoclonal antibodies and cytokine inhibitors targeting inflammatory pathways, including TNF-α and IL-1, have shown promise but remain limited by inconsistent efficacy and safety concerns. Long-acting biologic therapies—ranging from extended-release formulations, such as monoclonal antibodies and cytokine inhibitors, to gene therapy approaches—have emerged as promising strategies to enhance treatment durability and improve patient outcomes. Extracellular vesicles (EVs) have gained particular attention as a novel delivery platform due to their inherent stability, biocompatibility, and ability to transport therapeutic cargo, including biologics and immunomodulatory agents, directly to joint tissues. This review explores the evolving role of EVs in OA treatment, highlighting their ability to extend drug half-life, improve targeting, and modulate inflammatory responses. Additionally, strategies for EV engineering, including endogenous and exogenous cargo loading, genetic modifications, and biomaterial-based delivery systems, are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, UHealth Sports Medicine Institute, Miller School of Medicine, University of Miami, Miami, FL 33146, USA.
- Diabetes Research Institute, Cell Transplant Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
ORCID-Profile: Philip Drohat, Max Baron, Thomas M Best, Dimitrios Kouroupis
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Drohat, P., Baron, M., Kaplan, L. D., Best, T. M., & Kouroupis, D. (2025). Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy. Bioengineering, 12(5), 525. https://doi.org/10.3390/bioengineering12050525
Vancouver
Drohat P, Baron M, Kaplan LD, Best TM, Kouroupis D. Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy. Bioengineering. 2025;12(5):525. doi:10.3390/bioengineering12050525
BibTeX
@article{Drohat2025,
author = {Drohat, Philip and Baron, Max and Kaplan, Lee D and Best, Thomas M and Kouroupis, Dimitrios},
title = {Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy},
journal = {Bioengineering},
year = {2025},
volume = {12},
number = {5},
pages = {525},
doi = {10.3390/bioengineering12050525}
}
EUVIMED